Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

https://www.news-medical.net/news/20261110/Qureighte28099s-fibrosis-imaging-biomarker-selected-by-Contineum-Therapeutics-as-a-secondary-endpoint-in-Phase-2-PROPEL-IPF-clinical-trial.aspx Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.